Abcam Plc (ABC) Given Hold Rating at Numis Securities Ltd

Numis Securities Ltd reiterated their hold rating on shares of Abcam Plc (LON:ABC) in a research note issued to investors on Friday. They currently have a GBX 912 ($11.26) target price on the stock.

Several other research analysts have also recently issued reports on the company. Peel Hunt reissued a hold rating and issued a GBX 750 ($9.26) price target on shares of Abcam Plc in a research note on Friday. JPMorgan Chase & Co. reissued a neutral rating and issued a GBX 678 ($8.37) price target on shares of Abcam Plc in a research note on Tuesday, March 7th. Finally, Panmure Gordon reissued a sell rating and issued a GBX 680 ($8.40) price target on shares of Abcam Plc in a research note on Thursday, January 26th. One equities research analyst has rated the stock with a sell rating and five have issued a hold rating to the company. Abcam Plc has an average rating of Hold and an average target price of GBX 726 ($8.97).

Analyst Recommendations for Abcam Plc (LON:ABC)

Shares of Abcam Plc (LON:ABC) traded up 1.32% on Friday, reaching GBX 847.00. 975,767 shares of the company traded hands. The company’s market capitalization is GBX 1.71 billion. The firm has a 50-day moving average of GBX 863.26 and a 200-day moving average of GBX 828.85. Abcam Plc has a 52-week low of GBX 577.00 and a 52-week high of GBX 948.00.

Your IP Address:

The firm also recently declared a dividend, which will be paid on Thursday, April 13th. Stockholders of record on Thursday, March 16th will be paid a GBX 2.83 ($0.03) dividend. The ex-dividend date of this dividend is Thursday, March 16th. This represents a dividend yield of 0.31%.

Abcam Plc Company Profile

Abcam plc is a global life sciences company. As a developer of reagents and tools, the Company’s purpose is to serve life science researchers globally. Providing the research and clinical communities with tools and scientific support, the Company offers validated biological binders and assays to address important targets in critical biological pathways.

This story was originally published by sleekmoney ( and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at

Receive News & Ratings for Abcam Plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abcam Plc and related companies with's FREE daily email newsletter.


Leave a Reply

Your email address will not be published. Required fields are marked *